Annals of Allergy Asthma & Immunology最新文献

{"title":"In-flight epinephrine access during allergic emergencies","authors":"Sangeetha M. Kodoth MD , Niraj C. Patel MD, MS , Hyun J. Park MD, PhD , Joel P. Brooks DO, MPH","doi":"10.1016/j.anai.2025.07.004","DOIUrl":"10.1016/j.anai.2025.07.004","url":null,"abstract":"","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"135 4","pages":"Pages 450-451"},"PeriodicalIF":4.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144621099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ALERT (ChAracterizing uncontroLled sevERe asThma in Canada)","authors":"Andréanne Côté MD ,&nbsp;Jeffrey Beach HBA ,&nbsp;Jenna Reynolds BA (Hons) ,&nbsp;Koyo Usuba MS ,&nbsp;Joshua Tusin MSc ,&nbsp;Muthu K.G. Jayakumar PhD ,&nbsp;Tim Tian Yu Han PhD ,&nbsp;Susan Waserman MD","doi":"10.1016/j.anai.2025.07.005","DOIUrl":"10.1016/j.anai.2025.07.005","url":null,"abstract":"<div><h3>Background</h3><div>Approximately 230,000 to 465,000 patients in Canada have severe asthma; of these, 4% to 31% are uncontrolled. Despite increased availability of biologics, many rely on oral corticosteroids (OCSs) or short-acting β₂-agonists (SABAs), which are associated with substantial short- and long-term adverse effects.</div></div><div><h3>Objective</h3><div>ALERT aimed to characterize the demographics of patients with severe asthma and uncontrolled severe asthma with and/or without biologics in Canada and describe OCS/SABA and biologic treatment patterns.</div></div><div><h3>Methods</h3><div>ALERT was a retrospective descriptive study using longitudinal claims data from IQVIA’s private drug plan database and the Ontario drug benefits database. Adult patients with an inferred asthma diagnosis were assessed and selected using a rule-based inference algorithm and further classified as having severe asthma, uncontrolled severe asthma, and uncontrolled severe asthma without biologics, based on eligibility criteria including inhaled therapies and OCS use. Patients were assessed for OCS, SABA, and biologic use in the 12-month analysis period; regional variation was described.</div></div><div><h3>Results</h3><div>Patients with severe asthma, uncontrolled severe asthma, and uncontrolled severe asthma without biologics had a mean of 2.7, 4.4, and 4.2 OCS claims per patient per year, respectively. Of patients with uncontrolled severe asthma, 8.3% had ≥10 OCS claims. Combined OCS/SABA overuse (≥2 OCS/≥3 SABA claims in the study period) was recorded in 6.1% of patients with severe asthma. Most patients with uncontrolled severe asthma (71.8%) had no biologic claims. Regional disparities in OCS use were observed.</div></div><div><h3>Conclusion</h3><div>Optimization of asthma management through improved diagnosis, patient education, earlier specialist referral, and region-specific improvements is needed to reduce OCS/SABA use and increase biologic uptake for eligible patients.</div></div>","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"135 4","pages":"Pages 403-411.e3"},"PeriodicalIF":4.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144621095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Authors’ response","authors":"Yui Murai MD,&nbsp;Toshiyuki Koya MD, PhD,&nbsp;Hiroki Koda MD,&nbsp;Wakana Uji MD,&nbsp;Moe Tanaka MD,&nbsp;Masahiro Endo MD,&nbsp;Kyoichiro Oshima MD,&nbsp;Takahiro Matsuda MD,&nbsp;Hiroshi Ueno MD, PhD,&nbsp;Ami Aoki MD, PhD,&nbsp;Kenjiro Shima MD, PhD,&nbsp;Yosuke Kimura MD, PhD,&nbsp;Toshiaki Kikuchi MD, PhD","doi":"10.1016/j.anai.2025.06.030","DOIUrl":"10.1016/j.anai.2025.06.030","url":null,"abstract":"","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"135 4","pages":"Page 459"},"PeriodicalIF":4.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145183754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aspirin-exacerbated respiratory disease in the era of biologics","authors":"Tanya M. Laidlaw MD","doi":"10.1016/j.anai.2025.06.001","DOIUrl":"10.1016/j.anai.2025.06.001","url":null,"abstract":"<div><div><span>Aspirin-exacerbated respiratory disease (AERD) is a chronic, inflammatory syndrome defined by asthma, nasal polyposis<span>, and respiratory sensitivity to cyclooxygenase-1–inhibiting nonsteroidal anti-inflammatory drugs. Patients with AERD often experience severe nasal polyps, frequent sinus surgeries, impaired sense of smell, and persistent asthma. Traditional therapies, including corticosteroids, </span></span>endoscopic sinus surgery<span><span>, and aspirin desensitization, have offered symptomatic relief but are often limited by </span>adverse effects or short-lived efficacy. In recent years, the emergence of targeted biologics—including anti–interleukin-5/5Rα (mepolizumab and benralizumab), anti-IgE (omalizumab), anti–interleukin-4Rα (dupilumab), and anti–thymic stromal lymphopoietin (tezepelumab)—has significantly expanded the treatment landscape for AERD, providing nonsurgical options that directly modulate type 2 inflammation and improve both upper and lower airway symptoms.</span></div><div>This review synthesizes available data on the efficacy and applicability of each available biologic in AERD, highlighting benefits such as restoration of smell, reduced corticosteroid use, fewer surgical interventions, and potentially diminished nonsteroidal anti-inflammatory drug sensitivity. However, challenges remain. Biologics are costly and not universally accessible, long-term safety data are limited, and no reliable biomarkers currently exist to guide therapeutic selection. Not all patients respond to every agent, underscoring the need for personalized medicine approaches. Future directions include developing predictive biomarkers, conducting head-to-head biologic trials, and exploring earlier biologic interventions to modify disease progression.</div><div>Although not curative, biologics offer meaningful improvements in the quality of life for many patients with AERD. Ongoing research and innovation are essential to realize a future in which treatment decisions are guided by precision, accessibility, and sustained disease control.</div></div>","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"135 4","pages":"Pages 366-373"},"PeriodicalIF":4.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144259293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring new frontiers in eosinophilic chronic rhinosinusitis","authors":"Samer Abdelkader DO ,&nbsp;Liyan Mazahreh MD ,&nbsp;Ashton Ingold BS ,&nbsp;Dana Frederick MS ,&nbsp;Joshua L. Kennedy MD","doi":"10.1016/j.anai.2025.07.019","DOIUrl":"10.1016/j.anai.2025.07.019","url":null,"abstract":"","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"135 4","pages":"Pages 361-362"},"PeriodicalIF":4.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145183753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Authors' response","authors":"Michael W. Tsoulis MD, MSc ,&nbsp;Marcus S. Shaker MD, MS ,&nbsp;Marylee Verdi APRN, MSN ,&nbsp;Samuel Gubernick DO ,&nbsp;Jean Ly MD ,&nbsp;Dana V. Wallace MD","doi":"10.1016/j.anai.2025.06.013","DOIUrl":"10.1016/j.anai.2025.06.013","url":null,"abstract":"","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"135 4","pages":"Page 461"},"PeriodicalIF":4.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145183849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expanding clinical phenotype of truncating activation-induced cytidine deaminase variants","authors":"Connor Kuipers MD ,&nbsp;Lawrence Hennessey MD ,&nbsp;Nicholas L. Hartog MD","doi":"10.1016/j.anai.2025.07.002","DOIUrl":"10.1016/j.anai.2025.07.002","url":null,"abstract":"","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"135 4","pages":"Pages 454-455"},"PeriodicalIF":4.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144610249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of indolent mastocytosis and mast cell activation syndrome","authors":"Cem Akin MD ,&nbsp;Joseph H. Butterfield MD ,&nbsp;Mariana Castells MD, PhD ,&nbsp;Jonathan J. Lyons MD","doi":"10.1016/j.anai.2025.06.032","DOIUrl":"10.1016/j.anai.2025.06.032","url":null,"abstract":"<div><div>Knowledge and understanding of mast cell biology and mast cell disorders have increased in the past several years, with new classifications of diseases for both clonal and nonclonal forms. Along with these classifications has come differing treatment paradigms, including novel therapies now approved for various forms of clonal mast cell disorders. Unfortunately, there is some lack of guidance on how best to use these therapies. This yardstick aims to provide the clinician with a review of available therapies to treat mast cell activation syndrome and indolent systemic mastocytosis and an evidence-based expert opinion approach regarding on how best to use these therapies.</div></div>","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"135 4","pages":"Pages 466-477"},"PeriodicalIF":4.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144545927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and efficacy of outpatient drug challenges","authors":"Abhishek Bhandari MD ,&nbsp;Unaiza Faizan MD ,&nbsp;Allison Ramsey MD","doi":"10.1016/j.anai.2025.07.011","DOIUrl":"10.1016/j.anai.2025.07.011","url":null,"abstract":"","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"135 4","pages":"Pages 455-457"},"PeriodicalIF":4.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144668909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oh eosinophil, what can you tell us about asthma?","authors":"William W. Busse MD","doi":"10.1016/j.anai.2025.07.007","DOIUrl":"10.1016/j.anai.2025.07.007","url":null,"abstract":"","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"135 4","pages":"Pages 357-358"},"PeriodicalIF":4.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144621100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}